Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Ildiko LingvayMichelle GreenbergSilvina GalloHarry ShiJie LiuIra GantzPublished in: Diabetes, obesity & metabolism (2021)
Ertugliflozin added to insulin improved glycaemic control, BW and SBP versus placebo at 18 weeks in patients with T2DM and ASCVD.